Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing treatment for MDR TB. Results show good tolerability and treatment response at 6 months.
Keywords: Armenia; Belarus; Georgia; India; MDR TB; Russia; South Africa; Swaziland; Tuberculosis; antimicrobial resistance; antitubercular agents; bacteria; combination; delamanid; drug therapy; multidrug resistance.